Oxford Initiative Ignites New Hope in Fight Against Friedreich’s Ataxia

OXFORD, UK and CLEVELAND, Ohio – February 09, 2026 – A significant injection of philanthropic funding is set to accelerate the search for a cure for Friedreich’s Ataxia (FA), a rare and devastating neurodegenerative disease. The Oxford-Harrington Rare Disease Centre (OHC) announced today that its FA Alliance Innovation Fund has awarded £500,000 to five researchers at the University of Oxford, providing critical support for pioneering projects that could redefine the future for those living with the condition.

The awards, totaling £100,000 for each project, represent a targeted strike against a disease that currently has no cure. This move, backed by a philanthropic foundation, highlights a growing strategy in medical research: using strategic, early-stage funding to empower scientists to pursue high-risk, high-reward ideas that traditional funding bodies might overlook. For the thousands of families affected by FA worldwide, this news signals a renewed and powerful wave of hope.

A Relentless Disease in the Crosshairs

Friedreich’s Ataxia is a brutal, life-shortening condition that typically emerges in childhood or early adolescence. Caused by a genetic mutation that cripples the production of a vital protein called frataxin, the disease launches a progressive assault on the body. This frataxin deficiency leads to energy-starved cells, causing widespread damage to the nervous system, heart, and pancreas.

The onset is insidious, often starting with difficulty walking and a loss of balance. Over time, individuals face a cascade of worsening symptoms: slurred speech, profound fatigue, vision and hearing loss, and a debilitating loss of sensation. Most people with FA require a wheelchair within 10 to 20 years of their diagnosis. The heart is also a primary target, with hypertrophic cardiomyopathy—a dangerous thickening of the heart muscle—being the leading cause of premature death.

While the 2023 FDA approval of omaveloxolone marked a historic milestone as the first-ever treatment for FA, it slows progression rather than halting or reversing the disease. The unmet need for curative therapies remains immense. It is this gap that the new Oxford-based initiative aims to fill, targeting the disease from multiple, innovative angles.

Philanthropy as a Scientific Catalyst

The £500,000 investment stems from the FA Alliance Innovation Fund, an initiative established by the OHC in collaboration with a philanthropic foundation. This fund is specifically designed to be a catalyst, transforming nascent, ambitious concepts into viable research pathways.

"The first FA Alliance Innovation Fund awards mark a major milestone for OHC and the FA Alliance," said Professor Matthew Wood, Director and Chief Scientific Officer of OHC. "These projects capture the creativity and ambition needed to change the future for people with Friedreich’s Ataxia. They also show how philanthropy is being deployed to transform early ideas into real progress for patients."

This model is crucial for rare diseases, which affect an estimated 500 million people worldwide but often struggle to attract large-scale pharmaceutical investment due to smaller patient populations. Philanthropic funding can de-risk the earliest stages of research, providing the proof-of-concept data needed to attract larger grants and industry partnerships down the line.

Professor Carlo Rinaldi, one of the award recipients, underscored this point. "As researchers working on rare disease therapies, early support from philanthropy is often the difference between an idea that stalls and one that has the potential to change lives," he commented. "This award allows us to pursue a high-risk, high-reward approach to Friedreich’s Ataxia that could generate entirely new therapeutic possibilities."

A Multi-Pronged Scientific Assault on FA

The five funded projects represent a diverse and sophisticated attack on the core mechanisms of Friedreich’s Ataxia, leveraging cutting-edge science and technology.

Two projects focus on the promising field of epigenetics, which aims to reactivate the silenced FXN gene without altering the underlying DNA. Professor Carlo Rinaldi will explore "precision epigenetic therapy" to reverse the gene silencing, while Professor Esther Becker will investigate this process in advanced "cerebellar organoids"—three-dimensional miniature brain models grown from human stem cells.

The devastating cardiac impact of FA is the focus for Associate Professor Christopher Toepfer. His work will use cardiac organoids to investigate how epigenetic upregulation of frataxin can specifically treat FA-related cardiomyopathy, addressing the disease's most fatal complication.

Delving deeper into the molecular mechanics, Associate Professor Natalia Gromak’s project will use proteomics to identify the specific factors that interact with the expanded gene repeats causing the disease. Unmasking these molecular players could reveal entirely new targets for therapeutic drugs.

In a novel fusion of technology and therapy, Professor Andrea Németh, a consultant in neurogenetics, is developing an innovative digital tool. Her project combines therapeutic AI exercise gaming with motion capture technology to create a new way to objectively measure disease progression and potentially improve motor function, a critical need for both clinical trials and patient care.

The Power of a Global Alliance

This research push is not happening in a vacuum. It is coordinated by the FA Alliance at Oxford, a program established by the OHC in 2021. The alliance embodies a modern, collaborative approach to medical research, uniting 18 researchers, clinicians, and disease experts from across the University of Oxford and beyond.

This transatlantic partnership between the University of Oxford and the US-based Harrington Discovery Institute is further strengthened by its close ties to patient advocacy groups, including the Friedreich's Ataxia Research Alliance (FARA) in the US and Ataxia UK. These organizations provide not only funding support but also an invaluable link to the patient community, ensuring that research remains focused on their most pressing needs.

Jennifer Farmer, CEO of FARA, praised the collaborative model. “The FA Alliance established by Oxford-Harrington, brings together basic, translational and clinical researchers, and a multi-disciplinary approach, which we believe is essential for translating discoveries to treatments,” she stated. “The new research projects announced today...give individuals and families living with FA hope and confidence in our mission to treat and cure FA.”

Dr Julie Greenfield, Head of Research at Ataxia UK, echoed this sentiment, noting the importance of these advancements for the more than 10,000 people in the UK affected by ataxia.

By combining the academic rigor of Oxford, the drug development expertise of Harrington Discovery Institute, and the passionate advocacy of patient groups, the FA Alliance has created a powerful ecosystem for innovation. The new funding complements other initiatives like the FA Alliance Catalyst Fund, building a comprehensive pipeline that supports research from the earliest spark of an idea through to late-stage development, moving ever closer to a world free from the devastating impact of Friedreich’s Ataxia.